Neurofilament Heavy Chain (NfH) is a cytoskeletal protein expressed primarily in large myelinated axons. It is a sensitive biomarker for axonal injury and neurodegeneration[1].
| Property | Value |
|---|---|
| Category | Axonal Injury Biomarker |
| Target | NfH protein in CSF/blood |
| Sample Type | CSF, Plasma, Serum |
| Diseases | ALS, MS, AD, PD, stroke, TBI |
| Clinical Utility | Disease progression, treatment response |
Neurofilament heavy chain (NEFL/NfH) is one of three neurofilament subunits (NF-L, NF-M, NF-H) that form intermediate filaments in neurons. NfH has the highest molecular weight (~200 kDa) and contains multiple phosphorylation sites in its tail domain[2]. The phosphorylation state affects its electrophoretic mobility and can be detected using specific antibodies.
Neurofilaments are type IV intermediate filaments found specifically in neurons:
The heavy chain contains:
| Sample Type | Healthy Control | ALS | MS (active) | AD |
|---|---|---|---|---|
| CSF (pg/mL) | <500 | 800-5000 | 500-2000 | 400-1500 |
| Plasma (pg/mL) | <30 | 30-200 | 20-80 | 15-60 |
| Feature | NfH | NfL |
|---|---|---|
| Molecular Weight | ~200 kDa | ~61 kDa |
| Half-life in blood | Longer | Shorter |
| Specificity | More specific for CNS | Less specific |
| ALS sensitivity | High | Very high |
| Correlation with progression | Strong | Strong |
| Commercial assays | Limited | Extensive |
NfL is more widely used clinically, but NfH provides complementary information and may be more specific for certain conditions.
| Trial Phase | Use Case |
|---|---|
| Phase 1 | Safety, dose-finding |
| Phase 2 | Biomarker response, futility stopping |
| Phase 3 | Primary/secondary endpoint |
Neurofilament Heavy Chain (NfH) is a valuable biomarker for assessing axonal injury across multiple neurodegenerative and neurological conditions. While not disease-specific, it provides important information about disease severity, progression rate, and treatment response. The development of ultra-sensitive blood-based assays has expanded its clinical utility, making it increasingly accessible for routine monitoring and clinical trial applications.
The study of Neurofilament Heavy Chain (Nfh) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Petzold A, et al. Neurofilament heavy chain is a marker of axonal damage in ALS. Neurology. 2003. ↩︎
Lee MK, Cleveland DW. Neuronal intermediate filaments. Annu Rev Neurosci. 1996. ↩︎
Lu CH, et al. Neurofilament light chain: A prognostic biomarker in ALS. Neurology. 2015. ↩︎
Trentzsch M, et al. Neurofilament light chain as a marker for axonal damage in MS. Neurology. 2020. ↩︎
Zetterberg H, et al. Neurofilament light and tau as biomarkers in AD. Lancet Neurol. 2016. ↩︎
Benatar M, et al. Neurofilament light chain: A biomarker for ALS clinical trials. Ann Neurol. 2018. ↩︎
Gaiottino J, et al. Increased neurofilament light chain blood levels in neurodegenerative diseases. Neurology. 2013. ↩︎